Beta-2 Microglobulin-Deficient Cells - EP2699593

The patent EP2699593 was granted to University OF Washington Through ITS Center FOR Commercialization on Nov 4, 2020. The application was originally filed on Apr 18, 2012 under application number EP12720040A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2699593

UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
Application Number
EP12720040A
Filing Date
Apr 18, 2012
Status
Patent Maintained As Amended
Oct 2, 2020
Grant Date
Nov 4, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

JAMES POOLEMay 30, 2018 -

Patent Citations (11) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2008219956
DESCRIPTIONUS4892538
DESCRIPTIONUS5011472
DESCRIPTIONUS5837234
DESCRIPTIONWO9110425
DESCRIPTIONWO9110470
INTERNATIONAL-SEARCH-REPORTUS6514752
INTERNATIONAL-SEARCH-REPORTWO9209688
OPPOSITIONUS2005196404
OPPOSITIONUS6514752
OPPOSITIONWO9209688

Non-Patent Literature (NPL) Citations (11) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- AUet al., "An HLA-E single chain trimer inhibits human NK cell reactivity towards porcine cells", Molecular Immunology, (20050000), vol. 42, pages 1205 - 1214, XP027634988-
OPPOSITION- BICKNELL et al., "Beta 2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors", Proc. Natl. Acad. Sci. USA, (19940000), vol. 91, pages 4751 - 4755, XP055350173-
OPPOSITION- "Daudi (ATCC CCL-213)", www.Igcstandards-atcc.org, URL: https://www.Igcstandards-atcc.org/Product/All/CCL213.aspx?geo_country=gb#characteristics-
OPPOSITION- HANSEN et al., "Translational and basic applications of peptide-MHCI single chain trimers", Trend Immunol, (20100000), vol. 31, no. 10, pages 363 - 369, XP055514947-
OPPOSITION- HIRATA et al., "A knockout of beta-2-microglobulin in a human embryonic stem cell by AAV- mediated gene targeting", 7th Australasian Gene Therapy Society Meeting, Journal of Gene Medicine, (20110000), vol. 13, no. 7-8, pages 410 - 446, XP055514902-
OPPOSITION- LILIENFELD et al., "Transgenic expression of HLA-E single chain trimer protects porcine endothelial cells against human natural killer cell-mediated cytotoxicity", Xenotransplantation, (20070000), vol. 14, pages 126 - 134, XP055514962-
OPPOSITION- OBERMANN et al., "Peptide-beta2-microglobulin-major histocompatibility complex expressing cells are potent antigen-presenting cells that can generate specific T cells", Immunology, (20070000), vol. 122, no. 1, pages 90 - 97, XP002781133-
OPPOSITION- GRETEN et al., "Peptide-beta2-microglobulin-MHC fusion molecules bind antigen-specific T cells and can be used for multivalent MHC-Ig complexes.", Journal of Immunological Methods, (20020000), vol. 271, pages 125 - 135, XP002693603
OPPOSITION- TOSHITANI et al., "Expression of a single-chain HLA class I molecule in a human cell line: presentation of exogenous peptide and processed antigen to cytotoxic T lymphocytes.", Proc. Natl. Acad. Sci. USA, (19960000), vol. 93, pages 236 - 240, XP002051157
OPPOSITION- KOTSIOU et al., "Properties and Applications of Single-Chain Major Histocompatibility Complex Class I Molecules", Antioxidants & Redox Signalling, (20110000), vol. 15, no. 3, pages 645 - 655, XP055100634
OPPOSITION- MATSUNAGA et al., "Activation of antigen-specific cytotoxic T lymphocytes by beta 2-microglobulin or TAP1 gene disruption and the introduction of recipient-matched MHC class I gene in allogeneic embryonic stem cell-derived dendritic cells.", Journal of Immunology, (20080000), vol. 181, pages 6635 - 6643, XP055145645

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents